A primary goal of the clinical trials efforts of UPCI is to design, implement and analyze innovative, investigator-initiated pilot and phase 1 clinical trials. The development, initiation, implementation and completion of UPCI investigational studies receive substantial and essential support from UPCI Clinical Research Services (CRS). In 2008, 349 of the 1158 total UPCI patients (30%) participating in interventional clinical trials were entered onto institutional studies initiated by UPCI investigators. These investigatorinitiated trials focus on translational research and involve investigators from all of the translational and disease-specific programs of UPCI. Protocol-Specific Research Support has been instrumental in enabling several of these trials. Review of trials supported in the last grant cycle shows that the many PSRS supported trials advanced to the point of support by other mechanisms and/or publication of results. Requests for PSRS support of novel pilot or innovative phase I clinical trials are made by the PI at the time of submission of the trial to the Protocol Review Committee (PRC). Trials are evaluated for innovation and novelty, as well as availability of other sources of support, at the time of PRC submission. Trials with potential to be supported by PSRS funds are forwarded to the Associate Director of Clinical Investigation who makes recommendations to the Director of UPCI for final approval. Funds are used to support the effort of expert research nurses, termed Clinical Research coordinators, who can assist investigators with all aspects of trial implementation and execution.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-26
Application #
8705428
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
26
Fiscal Year
2014
Total Cost
$95,595
Indirect Cost
$32,356
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Vyas, Avani R; Moura, Michelle B; Hahm, Eun-Ryeong et al. (2016) Sulforaphane Inhibits c-Myc-Mediated Prostate Cancer Stem-Like Traits. J Cell Biochem 117:2482-95
Pollack, Ian F; Jakacki, Regina I; Butterfield, Lisa H et al. (2016) Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. J Neurooncol :
Concha-Benavente, Fernando; Srivastava, Raghvendra M; Trivedi, Sumita et al. (2016) Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res 76:1031-43
Posluszny, Donna M; Dew, Mary Amanda; Beckjord, Ellen et al. (2016) Existential challenges experienced by lymphoma survivors: Results from the 2010 LIVESTRONG Survey. J Health Psychol 21:2357-66
Delgado, Evan; Boisen, Michelle M; Laskey, Robin et al. (2016) High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome. Gynecol Oncol 141:348-56
Kirkwood, Caitlin M; MacDonald, Matthew L; Schempf, Tadhg A et al. (2016) Altered Levels of Visinin-Like Protein 1 Correspond to Regional Neuronal Loss in Alzheimer Disease and Frontotemporal Lobar Degeneration. J Neuropathol Exp Neurol 75:175-82
Chen, Mingqing; Sun, Fan; Han, Lei et al. (2016) Kaposi's sarcoma herpesvirus (KSHV) microRNA K12-1 functions as an oncogene by activating NF-κB/IL-6/STAT3 signaling. Oncotarget 7:33363-73
Gojo, Ivana; Beumer, Jan H; Pratz, Keith W et al. (2016) A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. Clin Cancer Res :
Blundon, Malachi A; Schlesinger, Danielle R; Parthasarathy, Amritha et al. (2016) Proteomic analysis reveals APC-dependent post-translational modifications and identifies a novel regulator of β-catenin. Development 143:2629-40
Rodler, Eve T; Kurland, Brenda F; Griffin, Melissa et al. (2016) Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. Clin Cancer Res 22:2855-64

Showing the most recent 10 out of 885 publications